Desuden var 64, 8% af patienterne som fik injektion med 3 mg hver 3. måned respondenter (defineret som et fald på ≥50% fra baseline), sammenlignet med 64, 9% af patienterne som fik 2, 5 mg daglig oralt.
In addition, 64.8% of patients receiving 3 mg every 3 months injection were identified as responders (defined as a decrease ≥ 50% from baseline), compared with 64.9% of patients receiving 2.5 mg daily orally.